Eating disorders are on the rise. GLP-1s could make things worse.
Source:
mitTechReview
October 30, 2026 · 02:00
From the publisher
GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,…
About the source
MIT Technology Review
MIT Technology Review is a bimonthly magazine wholly owned by the Massachusetts Institute of Technology. It was founded in 1899 as The Technology Review, and was re-launched without the leading article in its name on April 23, 1998, under then publisher R. Bruce Journey. In September 2005, it was changed, under its then editor-in-chief and publisher, Jason Pontin, to a form resembling the historical magazine.
Wikidata Q796078
Wikidata ↗
The original article opens on the publisher's website.
More from General
View topic →Trump focuses on Reflecting Pool in final public speech before midterms
cnbc
Nov 2, 2026 · 12:29
Intel foundry push faces critical test after stock's 45% plunge in October
cnbc
Nov 2, 2026 · 12:07
AI chatbots are becoming political advisers. Their answers can mislead voters
nprNews
Nov 2, 2026 · 12:02
Is America really that polarized? The answer might be a surprise
nprNews
Nov 2, 2026 · 12:00
Googling "Zelda" today offers a glimpse of how search worked in 1998
arsTechnica
Nov 2, 2026 · 11:52